Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by M101on Sep 21, 2021 1:57pm
212 Views
Post# 33892980

RE:RE:750,000 CAD Volume

RE:RE:750,000 CAD VolumeI'm actually surprised that the pp holders continue to liquidate at .18, although I expect it's still at no loss so free warrants.  The chart now looks like last year only at twice the time scale and ready to break downward any day, but I don't see the logic of doing so. 
Not that logic matters, trading is pathologic. At some point next year traders are going to start piling in for 18 months of P1 news so at what price to they expect to get back in? Goldstein's legacy is annoying but not life threatening.

There is something bigger going on, China. If you're paying attention to the cold war being waged against it then you know it's continuing to pick up assets that are grossly under valued by design of western monopolists. That MRNA vaccine asset fit an obvious immediate need but pharma is not their first concern, see coup in Guinea.
However China has a huge demographic problem as their birthrate has dropped below even Japan's and no amount of incentives seem to be turning that around, so AD is very soon going to be a pharma field they want to exploit.  
Meanwhile Rand Corp in 2016 basically advised US defense to turn the cold war into a regional hot one by 2025 or risk the window closing to stop B&R. Which is why AUKUS just happened, why the repositioning on Afghanistan, the NED funded street riots from HK to Myanmar, and Biden's continuation of Trump's bizarre China bashing.
  
Join the dots, big pharma is in for a shake-up and Promis is long gone by 2025 at any price it demands, don't sell on the first offer.  JMHO


 





 





<< Previous
Bullboard Posts
Next >>